WallStSmart

GlaxoSmithKline PLC ADR (GSK)vsToyota Motor Corporation ADR (TM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Toyota Motor Corporation ADR generates 154340% more annual revenue ($50.45T vs $32.67B). GSK leads profitability with a 17.5% profit margin vs 7.3%. GSK appears more attractively valued with a PEG of 0.50. GSK earns a higher WallStSmart Score of 70/100 (B).

GSK

Strong Buy

70

out of 100

Grade: B

Growth: 6.7Profit: 8.5Value: 10.0Quality: 5.5
Piotroski: 5/9Altman Z: 1.24

TM

Buy

53

out of 100

Grade: C-

Growth: 5.3Profit: 5.0Value: 7.3Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

GSKUndervalued (+66.0%)

Margin of Safety

+66.0%

Fair Value

$172.22

Current Price

$54.71

$117.51 discount

UndervaluedFair: $172.22Overvalued
TMSignificantly Overvalued (-96.6%)

Margin of Safety

-96.6%

Fair Value

$121.38

Current Price

$210.93

$89.55 premium

UndervaluedFair: $121.38Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GSK6 strengths · Avg: 9.2/10
PEG RatioValuation
0.5010/10

Growing faster than its price suggests

Return on EquityProfitability
43.3%10/10

Every $100 of equity generates 43 in profit

EPS GrowthGrowth
54.7%10/10

Earnings expanding 54.7% YoY

Market CapQuality
$104.12B9/10

Large-cap with strong market position

P/E RatioValuation
14.1x8/10

Attractively priced relative to earnings

Free Cash FlowQuality
$1.48B8/10

Generating 1.5B in free cash flow

TM2 strengths · Avg: 10.0/10
Market CapQuality
$273.41B10/10

Mega-cap, among the largest globally

P/E RatioValuation
11.8x10/10

Attractively priced relative to earnings

Areas to Watch

GSK3 concerns · Avg: 3.0/10
Price/BookValuation
10.1x4/10

Trading at 10.1x book value

Debt/EquityHealth
1.103/10

Elevated debt levels

Altman Z-ScoreHealth
1.242/10

Distress zone — elevated risk

TM4 concerns · Avg: 3.3/10
PEG RatioValuation
1.544/10

Expensive relative to growth rate

Price/BookValuation
11.2x4/10

Trading at 11.2x book value

Profit MarginProfitability
7.3%3/10

7.3% margin — thin

EPS GrowthGrowth
-42.3%2/10

Earnings declined 42.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : GSK

The strongest argument for GSK centers on PEG Ratio, Return on Equity, EPS Growth. Profitability is solid with margins at 17.5% and operating margin at 18.9%. PEG of 0.50 suggests the stock is reasonably priced for its growth.

Bull Case : TM

The strongest argument for TM centers on Market Cap, P/E Ratio.

Bear Case : GSK

The primary concerns for GSK are Price/Book, Debt/Equity, Altman Z-Score.

Bear Case : TM

The primary concerns for TM are PEG Ratio, Price/Book, Profit Margin.

Key Dynamics to Monitor

GSK profiles as a mature stock while TM is a value play — different risk/reward profiles.

GSK carries more volatility with a beta of 0.32 — expect wider price swings.

TM is growing revenue faster at 8.6% — sustainability is the question.

GSK generates stronger free cash flow (1.5B), providing more financial flexibility.

Bottom Line

GSK scores higher overall (70/100 vs 53/100), backed by strong 17.5% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

GlaxoSmithKline PLC ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

GlaxoSmithKline plc is dedicated to the creation, discovery, development, manufacture and marketing of pharmaceuticals, vaccines, over-the-counter drugs and health-related consumer products in the UK, US and internationally. The company is headquartered in Brentford, the United Kingdom.

Toyota Motor Corporation ADR

CONSUMER CYCLICAL · AUTO MANUFACTURERS · USA

Toyota Motor Corporation designs, manufactures, assembles and sells passenger cars, minivans and commercial vehicles, and related parts and accessories. The company is headquartered in Toyota, Japan.

Want to dig deeper into these stocks?